2CF24C43-7C9D-4395-8C82-5A80361F9980
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 48.65308804204993
- age_years
- 33
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.534
- MYC_TARGETS_V1+0.518
- MYC_TARGETS_V2+0.497
- DNA_REPAIR+0.419
- ADIPOGENESIS+0.416
- NOTCH_SIGNALING+0.409
- E2F_TARGETS+0.359
- FATTY_ACID_METABOLISM+0.340
- CHOLESTEROL_HOMEOSTASIS+0.326
- WNT_BETA_CATENIN_SIGNALING+0.298
Top 10 suppressed
- ANGIOGENESIS-0.448
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.365
- INFLAMMATORY_RESPONSE-0.331
- TNFA_SIGNALING_VIA_NFKB-0.306
- IL6_JAK_STAT3_SIGNALING-0.305
- ALLOGRAFT_REJECTION-0.304
- INTERFERON_GAMMA_RESPONSE-0.234
- APICAL_SURFACE-0.226
- KRAS_SIGNALING_DN-0.221
- MYOGENESIS-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 2482156E-29A8-4B6B-91BD-219EAC9229B5 | — | — | 0.920 |
| 2 | B9E0623C-E3AC-4B2B-983E-C2246AD0DB00 | — | — | 0.897 |
| 3 | 83BB732E-132F-4677-B70D-5ADE69831226 | — | — | 0.894 |
| 4 | C3818F8D-4E33-40AA-8863-E1CD71505597 | — | — | 0.882 |
| 5 | E3E4E7DA-AD14-44BA-B3BE-02652B3CEE18 | — | — | 0.881 |
| 6 | 4EBF33F3-DA34-4866-81E5-F2D50A18D413 | — | — | 0.875 |
| 7 | 1C94EA93-563D-4F65-B857-85EF91127874 | — | — | 0.873 |
| 8 | 9B1A0E7C-F8DB-4FA0-9259-42A988D4E040 | — | — | 0.871 |
| 9 | 743F5644-F650-437A-B4AE-4972F88606D8 | — | — | 0.865 |
| 10 | D0F8B6CA-5F3B-4B66-BCC5-72C17325DABF | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.534 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.518 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.497 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.419 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.416 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.409 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.359 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.340 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.326 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.298 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.286 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.285 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.274 | Inavolisib | — uncovered |
| PEROXISOME | 0.259 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.233 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.219 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.208 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.200 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.172 | Remibrutinib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.168 | Inavolisib | — uncovered |